Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

– Consistent safety and efficacy profiles across adult and pediatric populations –

Related Keywords

Seattle ,Washington ,United States ,American ,Sharon Klahre ,Neil Gallagher ,American Society Of Hematology Annual Meeting ,Twitter ,Syndax Pharmaceuticals ,Head Of Research ,Exchange Commission ,Linkedin ,European Commission ,Time Oncology Review Program ,Prnewswire Syndax Pharmaceuticals ,American Society Of Pediatric Hematology Oncology ,Syndax Pharmaceuticals Inc ,Plenary Session ,Acute Leukemia ,Meeting Presentations ,American Society ,Hematology Annual ,Orphan Drug Designation ,Fast Track ,Breakthrough Therapy Designation ,New Drug Application ,Priority Review ,Prescription Drug User Fee Act ,Real Time Oncology Review ,Rearranged Acute ,Private Securities Litigation Reform Act ,Region ,